Biểu đồ giá cổ phiếu CELC
CELC Tài chính
Celcuity Inc
$139.44
-1.58%
$-2.25
Khi đóng cửa: May 06, 16:00:00 GMT-4
$141.31
1.34%
$1.87
Phiên sau giờ: May 06, 20:00:00 GMT-4
Quay lại
Celcuity Inc (CELC) Tài chính
Thống kê chính
Giá đóng cửa trước
$141.69
Giá mở cửa
$140.55
Phạm vi ngày
$133.94 - $142.61
Phạm vi 52 tuần
$9.5 - $141.31
Khối lượng
801.5K
Khối lượng trung bình
760.0K
Tỷ suất cổ tức
--
EPS (TTM)
-3.78
Vốn hóa thị trường
$6.8B
CELC là gì?
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
